Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

NCT04943198 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
25
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Anna Raciborska

Collaborators